GSK plc (NYSE:GSK) Given Consensus Recommendation of “Buy” by Analysts

Shares of GSK plc (NYSE:GSK) have received an average rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $50.00.

GSK has been the subject of several recent research reports. Citigroup upgraded GSK to a “strong-buy” rating in a research report on Monday, June 24th. Jefferies Financial Group increased their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Argus raised shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th.

GSK Trading Up 0.1 %

NYSE GSK opened at $41.21 on Friday. The stock has a 50-day moving average of $39.73 and a 200-day moving average of $41.44. The company has a current ratio of 0.82, a quick ratio of 0.58 and a debt-to-equity ratio of 0.99. GSK has a 1-year low of $33.67 and a 1-year high of $45.92. The firm has a market cap of $85.41 billion, a PE ratio of 14.93, a price-to-earnings-growth ratio of 1.32 and a beta of 0.64.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be given a dividend of $0.3843 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date is Friday, August 16th. GSK’s payout ratio is presently 54.71%.

Institutional Investors Weigh In On GSK

A number of large investors have recently modified their holdings of GSK. Register Financial Advisors LLC purchased a new stake in GSK in the first quarter worth about $31,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of GSK in the 2nd quarter valued at approximately $37,000. Richardson Financial Services Inc. bought a new stake in shares of GSK during the fourth quarter valued at approximately $40,000. Newbridge Financial Services Group Inc. bought a new stake in shares of GSK during the first quarter valued at approximately $49,000. Finally, PrairieView Partners LLC purchased a new stake in GSK in the second quarter worth $47,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.